An observational study in Atrial Fibrillation, sponsored by Diagram B.V.. Completed at 1 site in Netherlands. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-12.
Sponsored by Diagram B.V. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 255 studies in Atrial Fibrillation with a site in Netherlands — 33 open to participants now, 49 under way, 2 of them phase 3. Atrial Fibrillation · Netherlands.
Among the 255 studies in Atrial Fibrillation with a site in Netherlands, this one is the 11th largest by enrollment of the 63 observational ones that give a count, is one of 11 that started in 2018, is one of 63 observational ones, and was the 177th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →33 of the 255 studies in Atrial Fibrillation with a site in Netherlands are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Netherlands, Belgium, Germany and 3 more countries
Ages 18+
Bayer · Sites in Netherlands, United States, Belgium and 5 more countries
Ages 18–85
Milestone Pharmaceuticals Inc. · Sites in Netherlands, United States, Canada
Ages 18+
Happitech BV · Sites in Netherlands, United States
Ages 22 min+
Novartis Pharmaceuticals · Sites in Netherlands, United States, Canada and 4 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
255 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 23 · Phase 3 33 · Phase 4 29
First in 2000; this study’s year is marked. 11 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,168 is above the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 250 across the 192 interventional studies, 400 across the 63 observational. Of the 185 that completed or were terminated, 72 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
135 of 255 have an industry lead sponsor. The 10 most frequent:
Diagram B.V. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Diagram B.V. has 3 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
13 of the studies in Atrial Fibrillation with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07779213Happitech BVDetection of Atrial Fibrillation Using PPG From Smartphone Cameras | 2026-11 |
| NCT06355063Pulse Biosciences, Inc.CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation | 2026-12-31 |
| NCT06106594Abbott Medical DevicesVOLT CE Mark Study | 2027-01 |
| NCT06808217Boston Scientific CorporationA Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation | 2027-04-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 255 studies in Atrial Fibrillation with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Although the condition itself is not life-threatening, the complications result in increased morbidity and mortality. AF is often asymptomatic and a considerable number of people suffering from AF are not aware of their condition. Unfortunately, a cerebral infarction is often the first clinical manifestation. The idea to screen subjects opportunistically for Asymptomatic Atrial Fibrillation (AAF) was infeasible until recently. However, with a recently-developed smartphone connected Mobile ECG Device (MED), this seems to be feasible after all.
The main objectives are:
Study design:
Prospective validation study.
The participants of this study will be subjects who visit their general practicioner or cardiologist or who visit the DETECT AF team at an event.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
Other: Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
Sensitivity of the mobile ECG device
Time frame: At screening
Specificity of the mobile ECG device
Time frame: At screening
Plan to share: Undecided — We have not yet decided to share the individual participant data.
No publications or documents are linked to this record.
Ran from Jul 2018 to primary completion in Apr 2021, 33 months.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 33 months is below that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Diagram B.V.